KEY - Investigation Alert Apellis Pharmaceuticals KeyCorp ACI Worldwide and Applied Digital: Johnson Fistel LLP Encourages Long-Term Investors to Submit Their Information Below | Benzinga
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) --
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Johnson Fistel, LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors.
If you have continuously owned Apellis Pharmaceuticals shares since before January 28, 2021, submit your information below:
https://www.cognitoforms.com/JohnsonFistel/ApellisPharmaceuticalsInc2
Recently a class action lawsuit was filed against the company. According to the complaint, during the class period, defendants represented SYFOVRE "demonstrated a favorable safety profile" with minimal adverse effects and "no events of retinal vasculitis or retinal vein occlusion" observed. Notwithstanding defendants' claims regarding the safety of SYFOVRE, on July 15, 2023, the American Society of Retina Specialists ("ASRS") published a letter highlighting concerns with SYFOVRE. Specifically, the ASRS indicated that physicians have reported cases of eye inflammation in patients treated with SYFOVRE, including six instances of occlusive retinal vasculitis, a type of inflammation that blocks blood flow through the vessels that feed the retina and potentially results in blindness. On this news, the price of Apellis common stock declined $32.04 per share, or nearly 38%, to close at $52.46 per share on July 17, 2023.
KeyCorp (NYSE:KEY)
Johnson Fistel, LLP is investigating potential claims on behalf of KeyCorp against certain of its officers and directors.
If you are a current, long-term shareholder of KeyCorp holding shares before February 27, 2020, you can click or copy and paste the link below in a browser to join this action:
https://www.cognitoforms.com/JohnsonFistel/KeyCorp
Recently a class action lawsuit was filed against KeyCorp. According to the complaint, one of the Company's principal sources of revenue is net interest income ("NII"), which is calculated as the difference between interest income received on ...